INTRODUCTION: Epidermal growth factor receptor (EGFR) mutations are more common in lung adenocarcinoma and in female patients of East-Asian origin. We aimed to assess the expression of female hormone receptors in East-Asian lung adenocarcinomas, their correlation with EGFR mutations, and prognostic significance. METHODS: Estrogen receptor (ER)alpha, ERbeta, progesterone receptor (PR), and Her-2 expression were examined using immunohistochemical methods on 109 lung adenocarcinoma cases. EGFR mutations were analyzed by partially denaturing high performance liquid chromatography. Association of hormone receptor with clinical factors was assessed using the Fisher's exact test. Associations with survival were assessed using the Cox proportional hazard model. RESULTS: Using scoring criteria routinely used for breast cancer, there were four (4%) ERalpha, one (1%) ERbeta, six (6%) PR, and one (1%) Her-2 positive cases. Considering any staining as positive, 14 (14%) ERalpha, 10 (9%) ERbeta, 12 (12%) PR, and 26 (24%) Her-2 cases were positive. Thirty-nine patients (39%) had EGFR mutations. ERalpha positivity was significantly associated with ERbeta and PR positivity. There were more EGFR mutations seen in tumors with ERbeta positivity (60%) compared with those with negative expression (37.9%), and there was a trend toward a poorer outcome for patients with tumor that were positive for ERbeta and Her-2. CONCLUSIONS: We found that ERalpha, ERbeta, PR, and Her-2 expression in lung adenocarcinoma are present but limited. This suggests that hormonal influence may not be an important factor to account for the high prevalence of lung cancer among the East-Asian women.
INTRODUCTION:Epidermal growth factor receptor (EGFR) mutations are more common in lung adenocarcinoma and in female patients of East-Asian origin. We aimed to assess the expression of female hormone receptors in East-Asian lung adenocarcinomas, their correlation with EGFR mutations, and prognostic significance. METHODS:Estrogen receptor (ER)alpha, ERbeta, progesterone receptor (PR), and Her-2 expression were examined using immunohistochemical methods on 109 lung adenocarcinoma cases. EGFR mutations were analyzed by partially denaturing high performance liquid chromatography. Association of hormone receptor with clinical factors was assessed using the Fisher's exact test. Associations with survival were assessed using the Cox proportional hazard model. RESULTS: Using scoring criteria routinely used for breast cancer, there were four (4%) ERalpha, one (1%) ERbeta, six (6%) PR, and one (1%) Her-2 positive cases. Considering any staining as positive, 14 (14%) ERalpha, 10 (9%) ERbeta, 12 (12%) PR, and 26 (24%) Her-2 cases were positive. Thirty-nine patients (39%) had EGFR mutations. ERalpha positivity was significantly associated with ERbeta and PR positivity. There were more EGFR mutations seen in tumors with ERbeta positivity (60%) compared with those with negative expression (37.9%), and there was a trend toward a poorer outcome for patients with tumor that were positive for ERbeta and Her-2. CONCLUSIONS: We found that ERalpha, ERbeta, PR, and Her-2 expression in lung adenocarcinoma are present but limited. This suggests that hormonal influence may not be an important factor to account for the high prevalence of lung cancer among the East-Asian women.
Authors: Sornsawan Kawprasertsri; Richard J Pietras; Diana C Marquez-Garban; Viroj Boonyaratanakornkit Journal: Cancer Lett Date: 2016-02-15 Impact factor: 8.679
Authors: Charlene Jin Yee Liew; Lester Chee Hao Leong; Lynette Li San Teo; Ching Ching Ong; Foong Koon Cheah; Wei Ping Tham; Haja Mohamed Mohideen Salahudeen; Chau Hung Lee; Gregory Jon Leng Kaw; Augustine Kim Huat Tee; Ian Yu Yan Tsou; Kiang Hiong Tay; Raymond Quah; Bien Peng Tan; Hong Chou; Daniel Tan; Angeline Choo Choo Poh; Andrew Gee Seng Tan Journal: Singapore Med J Date: 2019-11 Impact factor: 1.858
Authors: Ting-Yuan David Cheng; Amy K Darke; Mary W Redman; Gary R Zirpoli; Warren Davis; Rochelle Payne Ondracek; Wiam Bshara; Angela R Omilian; Robert Kratzke; Mary E Reid; Julian R Molina; Jill M Kolesar; Yuhchyau Chen; Robert M MacRae; James Moon; Philip Mack; David R Gandara; Karen Kelly; Regina M Santella; Kathy S Albain; Christine B Ambrosone Journal: J Natl Cancer Inst Date: 2018-07-01 Impact factor: 13.506